WHAT THIS PAPER ADDS This paper reports the impact of an optimized spinal cord protection strategy on spinal cord ischemia rates after endovascular thoracoabdominal aneurysm repair performed in a high volume center.
INTRODUCTION
The repair of descending thoracic and thoracoabdominal aortic aneurysms (TAAAs) exposes the spinal cord to ischemic injuries with resultant paraplegia or paraparesis. 1 Although intuitively less invasive than open repair, endovascular thoracic and TAAA repairs are nonetheless still associated with high rates of spinal cord ischemia (SCI), described, in a recent meta-analysis, in up to 13% of patients after thoracic endovascular aortic repair (TEVAR). 2 The mechanisms that cause SCI are thought to be infarction secondary to absolute low perfusion (loss of intercostals and poor collateral supply); reperfusion injury after transient per-procedural low perfusion; and microembolic "trash" arising from intra-aortic manipulation. The first two are theoretically amenable to modification by adjunctive therapies. While TEVAR has been studied, few reports to date have focused on SCI after TAAA endografting when evaluating these protocols aimed at spinal cord protection. 3, 4 A branched and fenestrated endograft programme for the treatment of atherosclerotic TAAA and chronic dissections was started at Aortic Centre, Hôpital Cardiologique, CHRU de Lille, in 2004. Before 2009, <20 endovascular TAAA repairs were performed annually. After 2009 the number of procedures increased to >30 annually. At the beginning of 2010 the endograft implantation technique (early restoration of blood flow to the pelvis and the lower limbs as soon as aortic components are implanted) was changed and a routine per-and post-operative proactive spinal cord protective protocol was adopted.
The purpose of this analysis was to assess the clinical impact of these spinal cord protective protocols.
METHODS
All TAAA endovascular repairs performed at the Aortic Centre, Hôpital Cardiologique, CHRU de Lille, between October 2004 and December 2013 were identified from a prospectively maintained electronic endovascular aortic database. Demographics, medical history, and procedure related data were extracted for analysis. The time of onset and severity of the neurologic deficit were determined by review of the electronic medical charts. Complications were defined using the Society for Vascular Surgery's reporting standards for endovascular aortic aneurysm repair. 5 Emergency procedures were excluded from the current analysis. The Crawford classification system was used to categorize the extent of the aortic coverage by the endograft (IeIV). 6e 8 Patients with three fenestrations (both renals and superior mesenteric artery [SMA]) and one scallop for the celiac trunk (CT), and a >20 mm proximal sealing zone above the SMA were included in the type IV TAAA group. Patients with type IeIII TAAAs treated between February 2010 and March 2012 were included in the "Windows 2" prospective multicenter trial. 9
Patient groups
Patients treated between 2004 and 2009 were included in group 1, and those treated from 2010 to 2013 were included in group 2. Since 2010, >30 TAAA endovascular repairs have been performed at the Aortic Centre, Hôpital Cardiologique, CHRU de Lille, annually. The year 2010 also coincides with the optimization of the device implantation technique and the systematic application of the proactive spinal cord protective protocol as described below.
Endovascular technique
One experienced vascular surgeon performed or supervised all of the procedures (S.H.). Prior to December 2012, all cases were performed in an operating room with a mobile motorized C-Arm (OEC 9900 Elite MD; GE OEC Medical Systems, Inc., Salt Lake City, UT, USA). More recently, they have been performed in a dedicated hybrid operating room (Discovery; GE Healthcare, Chalfont St Giles, UK) under image fusion guidance. The endovascular devices were all custom made three or four branched or fenestrated endografts, with proximal thoracic and/or distal abdominal bifurcated extensions when required. A dose of 100 UI/kg of intravenous heparin was injected at the beginning of the procedure. The anticoagulation was monitored by activated clotting time (ACT). The ACT target was >250 seconds during the entire procedure. A detailed description of the implantation procedure for fenestrated procedures has been published previously. 10 
Implantation protocol
In all cases, the branch/fenestration bearing component was implanted, and any fenestrations (cannulation and stenting) were completed in cases with a combination of fenestration(s) and branch(es). In group 1, any branches were then completed by implantation of the bridging stents into their respective branches from an axillary artery approach. Finally, procedures were completed by implantation of the bifurcated body and iliac limbs. Critically, the large sheaths were not withdrawn from the femoral and iliac arteries before the end of the procedure. In group 2, however, the implantation sequence was changed so that after implantation of the branch/fenestration bearing component and completion of any fenestrations, the bifurcated body and limb extensions were immediately completed to allow the early withdrawal of the large caliber (iliac occlusive) sheaths in order to permit the early restoration of blood flow to the pelvis and lower limbs and to reduce ischemia/reperfusion damage. The branches were then completed from an axillary arterial access as the final step. 10 Staged and adjunctive procedures to preserve spinal cord flow in group 2
Following the demonstration of the potentially beneficial effects of a staged repair to encourage spinal cord preconditioning during extensive TAAA repair, 11 the thoracic endovascular component was implanted during the first procedure in all cases in which the anatomy was suitable (i.e., when a distal sealing zone with a maximum diameter <42 mm was present). Every effort was made to maintain the perfusion of at least one internal iliac artery (IIA); if required, iliac branched devices were employed. When left subclavian artery (LSA) coverage was deemed necessary for proximal seal, carotid subclavian transposition or bypass was performed as an initial procedure. These "first stage" procedures were performed 6e10 weeks before definitive TAAA repair.
Proactive spinal cord protective protocol in group 2
Cerebrospinal fluid drainage. Since January 2010, a preoperative cerebrospinal fluid (CSF) drain has been systematically established for all TAAA types IeIII (not for type IV). A spinal drain is inserted in the operating room by a dedicated cardiovascular anesthesiology team. Owing to the risk of compressive neuraxial hematoma, the French Society of Anesthesiology recommends a minimum 6 hour delay between the placement of the CSF drain and injection of heparin. It is thus more convenient to place the spinal drain the day before the procedure. 12 CSF pressure was maintained at <10 cmH 2 O during and for at least 48 hours after the procedure. Continuous monitoring and recumbent positioning was performed in the intensive care unit (ICU) to avoid subdural bleeding and excessive CSF drainage. In patients without clinical evidence of SCI, CSF drains were removed 48 hours after the procedure. In the setting of documented SCI, CSF pressure was dropped to <5 cmH 2 O and the drain was removed after neurologic recovery (or at a maximum of 5 days after the procedure).
Pre-emptive use of blood products. At the end of the procedure, blood, plasma, and platelet transfusions were performed to avoid post-operative coagulopathy and blood loss. Fresh frozen plasma was transfused at 15 mL/kg and at least one pool of platelets was given, with therapeutic targets of hemoglobin >10 g/dL; prothrombin time >50%; plasma fibrinogen >2 g/L; and >100 G/L platelets.
Hemodynamic minima. Volume resuscitation and vasoactive support were administered to maintain a mean arterial pressure of 85e90 mmHg (invasive hemodynamic monitoring) and a central venous oxygen saturation >75% after endograft deployment.
Post-operative care. All patients were admitted to a dedicated cardiovascular ICU for continuous hemodynamic monitoring and hourly lower limb neurological assessment for at least the first 48 post-operative hours.
SCI diagnosis and management
SCI was defined as any new lower extremity motor or sensory deficit not attributable to other causes (epidural hematoma, intracranial pathology, peripheral neuropathy), and then further categorized according to a previously described neurologic deficit scoring system into paraplegia or paraparesis. 13 Patients who had a change in their preoperative neurologic status noted at the first postoperative examination were considered to have immediate SCI, whereas those who experienced an interval of normal post-operative neurological function, followed by a deficit, were considered to have a delayed presentation. When SCI was identified, a neurology consultation and magnetic resonance imaging (MRI) or an electromyogram (if MRI was not interpretable) was obtained.
End points
Primary end points included post-operative SCI, 30 day major and minor complications, and 30 day mortality. Mortality at 1 year was also recorded for patients operated on prior to December 2012.
Statistical analysis
Data were reported as median and 25e75% interquartile ranges and frequencies. Variables were compared between the two groups using the Fisher exact test for discrete data and the ManneWhitney test for continuous data. The groups were comparable with respect to age and comorbidities, and logistic regression analysis was therefore not performed. Because the most important factor that contributed to surgical risk was the extent of the aneurysmal disease, an analysis according to Crawford subgroup, excluding type IV TAAA endovascular repair (with the least risk of SCI), 14 was performed. Values of p < .05 were considered to be statistically significant. All analyses were conducted using Epi Info 3.5.3. software (Centers for Disease Control and Prevention, Atlanta, GA, USA).
RESULTS

Patient demographics and operative details
Between 2004 and December 2013, 204 endovascular repairs of TAAAs were performed (Fig. 1) . The total number of fenestrations was 523, including 322 renal, 147 SMA, and 54 CT fenestrations. The total number of branches was 172, comprising 64 renal, 54 SMA and 54 CT branches. Purely fenestrated endografts were implanted in 138 patients (23 in group 1 and 115 in group 2) and branched endografts in 33 patients (10 in group 1 and 23 in group 2). The remaining 33 patients were treated with grafts combining branches and fenestrations. Five (2.5%) type I, 38 type II (18.6%), 76 type III (37.3%), and 85 type IV (41.7%) TAAAs were treated. Between October 2004 and December 2009, 43 patients with TAAAs were treated (group 1), and between January 2010 and December 2013 a further 161 patients were treated (group 2). Patient demographic characteristics are summarized in Table 1 . The groups were comparable with respect to age and comorbidities.
Thirty day outcomes
Peri-operative outcomes are given in Table 2 . The overall 30 day mortality rate was 6.9%, the major complication rate was 26.5%, and the rate of SCI was 3.9%. The median length of procedure (skin to skin time) was 190 minutes (range 150e240 minutes) in group 1 and 180 minutes (range 150e 225 minutes) in group 2 (p < .01). Major complications were aortic/iliac rupture (n ¼ 2, 1%); SMA stent occlusion/ stenosis (n ¼ 3, 1.5%); access site major hematoma (n ¼ 3, 1.5%); peripheral macroembolization (requiring embolectomy) (n ¼ 5, 2.5%); access site infection (requiring drainage) (n ¼ 2, 1%); endograft infection (n ¼ 3, 1.5%); multi-organ failure (MOF; n ¼ 7, 3.4%); SCI (n ¼ 8, 3.9%); renal failure (requiring dialysis/filtration) (n ¼ 11, 5.4%, including five patients with MOF); pulmonary infection (n ¼ 9, 4.4%); bacteremia (n ¼ 5, 2.5%); cardiac failure/ arrest (n ¼ 7, 3.4%); stroke (n ¼ 2, 1%); bowel/hepatic ischemia (n ¼ 3, 1.5%); and pulmonary embolism (n ¼ 1, 0.5%). Five type I (2.5%) and two (1.0%) type III endoleaks were observed. The primary technical success rate was 92.6% (90.7% in group 1 and 93.2% in group 2).
Comparison between groups 1 and 2 revealed a significant difference in the incidence of SCI (14.0% vs. 1.2% respectively; p < .001). There were no major complications (intracranial hemorrhage) due to CSF drainage. In group 1, 24 patients were treated for type IeIII TAAAs; among these patients, 33.0% (8/24) had pre-operative spinal cord drainage. None of them had a staged procedure. In group 2, 95 patients were treated for type IeIII TAAAs; among these patients, 12.6% (12/95 patients) had a staged repair. The first procedure included seven TEVARs, one iliac conduit, three supra-aortic trunk debranching, four LSA transpositions and one renal fenestration.
Thirty day outcomes after type IeIII TAAA repair
The exclusion of the relatively low risk type IV TAAAs from analysis reveals a significant difference with regard to SCI rate ( 
Spinal cord injury
In total, SCI occurred in eight (3.9%) patients (Table 4 ). One died within 30 days and two others within a year of their procedure; one patient had no recovery and two others had partial recovery (able to walk alone with a stick). The two patients with delayed paraparesis experienced complete neurological recovery. All patients were transferred to a dedicated rehabilitation center. Peri-operative risk factors for SCI were identifiable in all cases: hemorrhagic/hemodynamic shock in four patients, extensive thoracic aortic coverage in all patients, IIA thrombosis in three patients (unilateral in two patients and bilateral in one), and renal insufficiency in one patient. Previous infrarenal abdominal aortic aneurysm repair was not a risk factor for SCI in this study.
Windows 2 results
This study included 23 patients who were part of a multicenter French trial (Windows 2) between February 2010 and March 2012 (all drawn from group 2 in the current study). 9 All were type IeIII TAAA repairs. This subgroup experienced six (26.1%) major complications, 10 (43.5%) minor complications, no 30 day mortality (0%), no SCI (0%), and six (26.1%) deaths at 1 year (three were considered in hospital deaths: acute renal failure, pneumonia, and aortic rupture due to endograft infection 43, 167, and 103 days after the initial procedure, respectively).
One year survival
The overall 1 year survival among patients treated before 2013 was 122/149 (81.9%) for the whole group, 37/43 (86%) in group 1, and 85/106 (80.2%) in group 2 (p ¼ .28). There was only one (1.0%) aneurysm related death in group 2, 103 days after the initial procedure as a consequence of an endograft infection.
DISCUSSION
This study describes the second largest published cohort of patients treated for TAAA using endovascular repair in a single, high volume center. Outcomes for patients treated at the beginning of the experience have been specifically compared with those treated after the initial "learning curve". The influence of a group of factors has been examined: the onset of a high annual experience (>30 procedures annually); a change in the device deployment sequence (specifically intended to produce an early restoration of blood flow to the pelvis); the application of an aggressive, per-and post-operative protocol (designed to optimize spinal cord perfusion). When comparing these two groups, it was observed that this combination of factors is associated with a reduced incidence of SCI. A significant reduction in the frequency of major complications when treating type IeIII TAAAs (but not type IV) was also observed.
The object of an effective spinal protection protocol is to prevent nerve cell death by preserving perfusion at cellular level and by reducing cellular metabolic demand. As spinal cord oxygen delivery is a compound of hemodynamic and oxygen content factors, it is therefore likely that augmentation of the cardiac function and reduction of the CSF pressure are key factors in optimal spinal perfusion. 15 At present, there is little consensus regarding the role of CSF drainage. 2 In a meta-analysis, series reporting routine, none, or selective prophylactic drain placement reported pooled SCI rates of 3.2%, 3.47%, and 5.6%, respectively. 2 This useful adjunct also carries the risk of intracranial hemorrhage. 16 Prophylactic CSF drainage was routinely performed pre-operatively before type IeIII TAAA repair in the later experience: the patients suffered no major complication attributable directly to CSF drainage and SCI rates were reduced, although it is not possible to determine the distinct role of CSF drainage from the protective strategies employed as a package.
In addition to universal CSF drainage, a pre-emptive strategy of blood, plasma and platelet transfusions was routinely performed for the following reasons. Firstly, extensive endovascular exclusion in large aneurysms is associated with massive blood sequestration between the aneurysmal aortic wall and the endograft. This results in an acute reduction in coagulation factors and platelets, which gives rise to a variety of coagulation disorders that contribute to severe bleeding. 17 Secondly, a maximization of oxygen delivery was attempted, in part based on an increased cardiac output. 3 Finally, perfusion with oxygen or hemoglobin depleted blood is physiologically valueless. A high hemoglobin level (at least 10 g/dL) and SaO 2 >95%, were therefore ensured. In addition, early pelvic and leg reperfusion is aimed for by the early removal of large femoral sheaths in order to reduce the pelvic and the lower limb ischemia time, and therefore reduce the likelihood and severity of any ischemia/reperfusion syndrome. The "collateral network concept" includes the idea of a remodeling process driven by pressure gradients across paraspinal collaterals. 18 This implies that a "staged approach" has the potential to reduce SCI by arteriogenic preconditioning. 11 This concept was introduced into the authors' clinical practice in 2010, and a "staged approach" was performed in 12/95 (12.6%) patients with type IeIII TAAAs.
A significant reduction in the SCI rate after TAAA repair has been observed, from 14.0% in the authors' early experience to 1.2% in their later experience. The majority of this improvement is ascribed to the routine application of all of the neuroprotective strategies described above as a package. The "learning curve" is more than a technical exercise, but it is likely that there is benefit to be gained from high case volumes and improving technical expertise. It has been widely reported that an important determinant of operative outcome is the volume of TAAA repairs. 19 
Study limitations
Most of these data were collected from a prospectively maintained electronic database but some details were gleaned from other, less reliable sources. For example, complete hemodynamic data for the period after patients were discharged from ICU (two patients developed SCI after discharge from the ICU) was not obtained. As these data describe a single, high volume centre experience, a multicenter study is required before advocating more definitive conclusions regarding the optimal spinal cord protection strategies that have been employed in this study. The specific role of each component of the SCI protection package has not been dissected because, at this stage of the experience, it is considered that the use of all of the components is both complimentary and important. As previously detailed, a number of changes have been made that have resulted in a significant reduction in the rates of SCI; it is not possible to evaluate how much each change has contributed to the improved results.
Conclusion
A spinal cord protection strategy, based on an optimization of the implantation procedure (including early restoration of pelvic and lower limb blood flow, aggressive revascularization of the LSA and the IIA, and performing staged repairs whenever possible) together with systematic CSF drainage, assiduous blood pressure management, and a strategy of pre-emptive of blood, plasma, and platelet transfusion, has been improved. This proactive spinal cord protective protocol associated with a high volume practice has significantly reduced the incidence of SCI after TAAA endovascular repair.
